Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bortezomib + docetaxel + cisplatin
- Development stage
- Phase 2
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy regimen consisting of bortezomib (a proteasome inhibitor), docetaxel (a taxane), and cisplatin (a platinum-based agent). This triple combination targets multiple pathways in cancer cells. Bortezomib inhibits the 26S proteasome leading to cell cycle arrest and apoptosis, docetaxel binds to microtubules preventing cell division, and cisplatin forms DNA adducts causing DNA damage and cell death. The combination may provide synergistic anticancer effects across various malignancies.
02
Targets
PSMB5 (Proteasome subunit beta Type-5)DNAMicrotubuleTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bortezomib + docetaxel + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bortezomib + docetaxel + cisplatin.